Health Care [ 9/12 ] | Biotechnology [ 63/75 ]
NASDAQ | Common Stock
CureVacN. V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVacN. V. was founded in 2000 and is headquartered in Tübingen, Germany.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 12, 24 | 1.50 Increased by +781.82% | 0.61 Increased by +145.90% |
Aug 15, 24 | -0.35 Decreased by -16.07% | -0.26 Decreased by -33.92% |
Apr 25, 24 | -0.39 Decreased by -44.44% | -0.18 Decreased by -116.67% |
Mar 12, 24 | -0.42 Increased by +36.36% | -0.20 Decreased by -110.00% |
Nov 14, 23 | -0.22 Increased by +12.00% | -0.23 Increased by +4.35% |
Aug 17, 23 | -0.30 Increased by +3.23% | -0.24 Decreased by -25.00% |
May 30, 23 | -0.27 Decreased by -237.50% | -0.34 Increased by +20.59% |
Dec 31, 22 | -0.66 Increased by +14.29% | -0.34 Decreased by -94.12% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 24 | 493.90 M Increased by +2.90 K% | 338.04 M Increased by +794.40% | Increased by +68.44% Increased by +123.17% |
Jun 30, 24 | 14.44 M Increased by +90.47% | -72.54 M Decreased by -7.61% | Decreased by -502.51% Increased by +43.50% |
Mar 31, 24 | 12.37 M Increased by +5.85% | -70.55 M Increased by +45.22% | Decreased by -570.22% Increased by +48.24% |
Dec 31, 23 | 22.57 M Increased by +93.06% | -86.65 M Increased by +32.71% | Decreased by -383.98% Increased by +65.15% |
Sep 30, 23 | 16.48 M Increased by +47.01% | -48.68 M Decreased by -2.34% | Decreased by -295.34% Increased by +30.39% |
Jun 30, 23 | 7.58 M Decreased by -62.38% | -67.41 M Decreased by -17.07% | Decreased by -889.48% Decreased by -211.19% |
Mar 31, 23 | 11.69 M Decreased by -71.65% | -128.78 M Decreased by -6.55 K% | Decreased by -1.10 K% Decreased by -23.36 K% |
Dec 31, 22 | 11.69 M Decreased by -71.65% | -128.78 M Decreased by -6.55 K% | Decreased by -1.10 K% Decreased by -23.36 K% |